Skip to main content
. Author manuscript; available in PMC: 2018 May 21.
Published in final edited form as: Sci Signal. 2017 Jun 6;10(482):eaah7177. doi: 10.1126/scisignal.aah7177

Fig. 7. TERS-primed murine prostate cancer cells have improved cellular fitness in vitro and in vivo.

Fig. 7

(A) Cartoon of coculture experimental design. Briefly, RFP-tagged TC1 cells (TC1-RFP) are primed with homologous Veh CM, whereas untagged TC1 cells are primed with TERS CM. After priming, cell populations are cocultured overnight and subsequently challenged. (B) Flow cytometry analysis to determine the percent RFP+ (vehicle-primed) and RFP− (TERS-primed) TC1 cells, 7AAD excluded, after 24-hour treatment with Tg, 2-deoxyglucose (2DG), bortezomib, or paclitaxel (n = 2 per coculture; at least 10,000 events were analyzed per condition). (C) Growth kinetics of vehicle- or TERS-primed TC1 cells subcutaneously injected into immunocompetent C57BL/6 mice (n = 5 per group). (D) Weight of vehicle- or TERS-primed tumors after 30 days. (E) Gross visualization of excised tumors. **P < 0.01, Student’s t test (paired two-tailed). Error bars are SEM. Data are representative of two independent experiments.